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ions can be developed to prevent these errors before they
ccur.
oi:10.1016/j.ijid.2010.02.2029
5.006
omparison of the effectiveness of low dose Indi-
avir/ritonavir (IDV/r) versus Atazanavir/ritonavir (ATV/r)
ased antiretroviral therapy in NNRTI experienced HIV-1
nfected patients in India
. Patel1,∗, A.K. Patel1, J.K. Patel1, E. Naik2, J. Duan2, R.
anjan1, S. Hamisu2
Vedanta Institute of Medical Sciences, 380009, Gujarat,
ndia
University of South Florida, Tampa, FL, USA
Background: Currently, data on the effectiveness of sec-
nd line antiretroviral regimens using IDV/r and ATV/r along
ith two back bone nucleosides in resource poor settings
s limited. It is important to compare the potency and efﬁ-
acy of each regimen in order to establish utility on clinical
utcomes. We sought to evaluate viro-immunologic deter-
inants of response to IDV400/r BID and ATV300/r QD in
re-treated HIV-infected patients.
Methods: Prospective cohort study on 441 patients who
xperienced immunological or clinical failure to ﬁrst line
NRTI-based treatment and were enrolled in a 96-week
tudy follow-up. Based on the patients ability to pay, 321
72.8%) and 120 (27.2%) patients were prescribed reg-
mens containing low dose of IDV/r 400/100mg BID or
TV/r 300/100mg QD with 2NRTI, respectively. Successful
mmunologic response to treatment was deﬁned by annual
ise in absolute CD4 count of 100/cmm or more from base-
ine, while successful virologic response was deﬁned by
VL < 400 copies/ml at 12 or 24 weeks after initiation of
reatment. Multivariate Cox Proportional Hazards Model was
sed to assess comparative effectiveness of treatment regi-
ens with correction for intra-cluster correlation by means
f the Robust Sandwich Estimator.
Results: Both the groups had similar age, sex and weight
istribution. (p = 0.302, 0.232 & 0.459 respectively). A total
f 63 patients (14.8%) had failed second line treatments, 53
atients (17.2%) were using IDV/r while 10 patients (8.5%)
ere on ATV/r. Patients who took IDV/r were more than
wice as likely to experience treatment failure as com-
ared to those on ATV/r (HR 2.18; 95% CI 1.14, 4.15). A
igniﬁcant treatment-response interaction was observed for
atient weight and prior combination of NRTI use. Success-
ul response was not different between the two groups when
atients weighed < 55 kg at baseline (log rank p value = 1.00)
n contrast to the ﬁndings among individuals weighing ‘‘55 kg
p = <0.0001). Patients with one NRTI recycled, ATV/r was
ound to be superior to IDV/r (p = 0.01) while among those
ith both NRTI recycled, there was no difference in response
o either group (p = 0.61).
Conclusion: We found that Successful response to second
ine therapy was twice as likely in the ATV/r group; however,
his difference was eliminated in patients less than 55 kg.
oi:10.1016/j.ijid.2010.02.2030
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RTI resistance proﬁle of the subtype F HIV-1 strains from
hildren and adolescents treated with multiple antiretro-
iral drugs
. Jugulete1,∗, M.L. Luminos2, M. Mardarescu3, D. Otelea4,
. Merisescu5
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, sector 2, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Disease ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases, Bucharest, Romania
Background: The HIV epidemic in Romania is character-
zed by the existence of a large cohort of children and
dolescents that have been infected in the late eighties.
ost of these patients have been under treatment for the
ast ten years: all of them are currently on HAART but
heir majority has experienced a period (years) of either
onotherapy (AZT) or bitherapy (AZT with 3TC or ddC). This
tudy examines resistance proﬁles in the RT gene of HIV-1
trains obtained from these patients.
Methods: We have studied resistance tests on antiretro-
iral therapy of experienced children’s and adolescents with
IV infection and AIDS hospitalized in National Institute
f Infectious Diseases ‘‘Prof. dr. Matei Bal#’’. On these
atients we have evaluated: antiretroviral therapy, number
f antiretroviral schemes, the type of resistance muta-
ions selected on Nucleoside Reverstranscriptase Inhibitors
NRTI’s) and the implications on to established of antiretro-
iral therapy, also.
Results: The most frequent mutations were: M184V/I -
8.8%, T215F/Y — 74.4%, D67N — 68.2%, K219E/Q — 66.6%,
70R — 56.9%, M41L — 41.4%. The thymidine analogue
utations (TAMs) were common and frequently associated
ith M184V. Within the TAM group, T215F/Y was frequently
ssociated with D67N, K70R and/or K219E/Q. V75T/V was
ssociated with K219E but only seldom with K219Q. The mul-
iresistention on experimented HIV infected children was
.2% (Q151M, 69ins, K65R).
Conclusion: The mutation associations in the RT gene
f the subtype F HIV-1 strains are partly different from
hose communicated for the subtype B strains and therefore
equire further scrutiny.
oi:10.1016/j.ijid.2010.02.2031
5.008
mplementation of HLA-B*5701 genetic screening prior to
bacavir prescription in Georgia
. Dvali ∗, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M.
archava, L. Gatserelia, T. TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research
enter, Tbilisi, Georgia
Background: A hypersensitivity reaction to abacavir
evelops in approximately 2-8% of patients receiving this
